What does Autolus Therapeutics do?
Autolus Therapeutics plc is a Nasdaq-listed biopharmaceutical company focused on programmed autologous T-cell therapies for cancer and autoimmune disease. Its defining asset is AUCATZYL, or obe-cel, a CD19 CAR T therapy approved in the United States for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. FDA approval arrived on November 8, 2024, followed by the first U.S. sale in January 2025. The FDA product page for AUCATZYL confirms the indication and approval record.
Which capabilities define the company?
Autolus combines modular cell programming, clinical development and commercial manufacturing. Its platform uses modules for advanced targeting, pharmacological control and activity enhancement. The official company overview also highlights more than 95 patent families and a fully enclosed, semi-automated manufacturing process. CAR T economics depend on both clinical efficacy and reliable, timely production of each patient-specific batch.
| Area | Current role | Why it matters |
|---|---|---|
| AUCATZYL | Commercial product in the U.S. and U.K. | Only current product-revenue engine and the proof point for the platform. |
| Obe-cel expansion | Pediatric ALL, lupus nephritis and progressive MS studies | Tests whether one cell-therapy backbone can support multiple indications. |
| Additional pipeline | AUTO1/22, AUTO8 and earlier programs | Provides optionality beyond a single commercial molecule. |
| Nucleus facility | Dedicated Stevenage manufacturing site | Controls quality, delivery and a major part of future gross-margin improvement. |
How does Autolus make money?
Autolus earns most revenue from AUCATZYL, but the model is more complex than a conventional drug sale. A patient’s cells are collected, programmed, expanded and returned for split-dose infusion. Revenue is recognized after final administration, net of U.S. rebates, chargebacks and assistance deductions. The cash-conversion cycle is therefore operationally intensive.
Which revenue stream matters most?
In FY2025, product revenue was $74.3 million and license revenue was $1.1 million, or 98.6% and 1.4% of total revenue. Licensing can arise from binders, technology options and partnerships, but it is lumpy. The company’s 2025 Form 10-K shows the transition clearly: FY2024 revenue was primarily licensing, while FY2025 was the first full commercial sales year.
What do the latest 2026 results show?
The quarter ended March 31, 2026 showed commercial progress without enterprise-level profitability. Net product revenue reached $26.2 million, up 192% from $9.0 million in Q1 2025, mainly because more doses were administered in the U.S. and newly launched U.K. market.
Why was positive gross margin a meaningful milestone?
Cost of sales was $24.6 million, leaving $1.6 million of gross profit. This matters because FY2025 cost of sales exceeded revenue; higher throughput is beginning to absorb fixed manufacturing costs. The company’s Q1 2026 earnings release also reiterated full-year AUCATZYL revenue guidance of $120 million to $135 million and continued positive gross margin for 2026.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Net product revenue | $26.2M | $9.0M | Dose volume and the U.K. launch drove 192% growth. |
| Cost of sales | $24.6M | $18.0M | Still high, but revenue finally exceeded product cost. |
| R&D expense | $21.2M | $26.7M | Down 21% as trial and clinical-manufacturing spend declined. |
| SG&A expense | $40.0M | $29.5M | Commercial build-out and one-time termination costs raised spending. |
| Operating loss | $59.5M | $65.2M | Improved, but remained more than twice quarterly revenue. |
| Net loss / ordinary share | $71.6M / $0.27 | $70.2M / $0.26 | Interest, foreign exchange and other expenses kept the bottom line deeply negative. |
Which turning points shaped Autolus?
Autolus is best understood through scientific, financing, manufacturing and regulatory turning points. Its official history traces the company from an academic spinout to commercial launch.
-
2014Autolus was spun out of University College London around cell-programming technology pioneered by Dr. Martin Pulé. The academic origin still shapes the modular platform and UCL licensing economics.
-
2018The company completed its Nasdaq IPO and reorganized as Autolus Therapeutics plc, creating access to public equity for expensive clinical development.
-
2021-2022Blackstone committed up to $150.0 million of development support for obe-cel, including a $50.0 million upfront payment and two $35.0 million milestone payments in 2022.
-
2023-2024Autolus built and qualified the Nucleus manufacturing operation in Stevenage, converting manufacturing from a supporting function into a strategic asset.
-
2024BioNTech invested $200.0 million in equity and entered technology and revenue-interest arrangements; FDA approval of AUCATZYL followed in November.
-
2025U.S. commercialization produced $74.3 million of product revenue. U.K. authorization, NICE recommendation and EU authorization broadened the regulatory footprint.
-
2026The U.K. launch began, Q1 gross margin turned positive and management announced a 13% workforce reduction designed to lower annual operating expense by about $15.0 million from 2027.
What changed when Autolus became commercial?
Commercialization shifted the critical bottleneck from clinical proof to execution. The company must now coordinate physician adoption, treatment-center readiness, patient logistics, manufacturing release, payer access and post-treatment safety monitoring. It also changed accounting: manufacturing employees and facility costs moved from R&D toward inventory and cost of sales, while SG&A rose to support U.S. and U.K. launch activity. The historical lesson is that approval did not reduce capital intensity; it changed where the costs appear and which operational failures matter most.
What gives AUCATZYL and Autolus a competitive advantage?
Obe-cel uses a CD19 CAR with a fast target-binding off-rate intended to mimic physiological T-cell interactions. Autolus argues that this can limit excessive activation and support persistence. The company’s obe-cel product page describes the mechanism and the rationale for durable activity with lower severe immunotoxicity.
Is the manufacturing network part of the moat?
Yes, but it is also a cost risk. Nucleus is roughly 70,000 square feet, and the 10-K discusses capacity of about 2,000-2,500 batches annually. Capacity ahead of current volume can support growth, but underutilization depresses gross margin. Manufacturing is therefore both a strategic option and a fixed-cost burden.
The harder-to-replicate resource is the bundle of programming know-how, clinical data, approval, manufacturing and treatment-center experience. Larger rivals still have more resources to influence referrals and fund earlier-line studies.
Who are Autolus Therapeutics' main competitors?
Tecartus from Kite/Gilead is the clearest direct comparator because it is also approved for adult relapsed or refractory B-cell precursor ALL. Kymriah serves patients up to age 25, while Breyanzi and Yescarta shape expectations in other CD19 malignancies. Bispecifics, antibody-drug conjugates and small molecules can also alter treatment sequencing.
| Competitive pressure | Examples named in the 2025 10-K | Strategic implication |
|---|---|---|
| Adult ALL CAR T | Tecartus | Most direct contest for eligible adult referrals, payer access and center preference. |
| CD19 CAR T ecosystem | Kymriah, Breyanzi, Yescarta | Defines operational benchmarks and may move into adjacent or earlier treatment lines. |
| Autoimmune CAR T | Cabaletta, Kyverna, Novartis, Juno/BMS, Cartesian | Could challenge obe-cel before Autolus establishes efficacy and scalable access in lupus nephritis. |
| In-vivo CAR T | Umoja, Capstan, Interius, EsoBiotec | A successful in-body programming approach could reduce the logistical disadvantage of autologous manufacturing. |
Where does Autolus appear best positioned?
Autolus is best positioned in adult r/r B-ALL, where AUCATZYL has approval and real-world use. Filings cite roughly 3,000 addressable adults in the U.S. and EU, but treated demand depends on referrals, fitness, payer approval and manufacturing. The company can build a franchise by winning this defined population and reusing infrastructure in adjacent indications.
Which pipeline programs could expand the story?
Autolus is expanding obe-cel while retaining additional programs. AUCATZYL provides manufacturing and safety experience; the pipeline tests whether those advantages transfer to younger ALL patients and autoimmune disease. The official pipeline overview identifies obe-cel, AUTO1/22 and other programmed T-cell candidates.
Why is autoimmune expansion strategically important?
Autoimmune disease could be larger than adult ALL, but it demands a different benefit-risk profile. These patients may tolerate intensive treatment less readily than late-line oncology patients. Autolus argues that obe-cel’s controllability and manufacturing package may help. CARLYSLE included nine infused adults with severe refractory lupus, and 50 million cells was selected for Phase 2.
| Program | Stage at Q1 2026 | Next disclosed milestone | Value-creation question |
|---|---|---|---|
| AUCATZYL adult ALL | Commercial | $120M-$135M FY2026 product-revenue guidance | Can volume and manufacturing efficiency sustain positive gross margin? |
| CATULUS pediatric ALL | Phase 2 portion enrolling | Data by year-end 2027 | Can obe-cel gain a younger-patient label in a market where Kymriah is established? |
| LUMINA lupus nephritis | Phase 2 enrolling | Data in 2028 | Can a one-time cell therapy produce durable immune reset with acceptable safety? |
| BOBCAT progressive MS | Phase 1 enrolling | Initial data by year-end 2026 | Can CAR T cells affect refractory progressive neurologic disease? |
| ALARIC AUTO8 | Phase 1 ongoing | Initial data by year-end 2026 | Does the wider platform create a second differentiated asset? |
How financially strong is Autolus?
Autolus has meaningful liquidity but is not self-funding. Cash and marketable securities totaled $229.4 million at March 31, 2026, down from $300.7 million at year-end 2025. Management expects resources, including anticipated AUCATZYL revenue, to fund operations into Q4 2027. The Q1 2026 Form 10-Q provides the detailed liquidity and cash-flow disclosure.
What does the cash-flow profile reveal?
FY2025 operating cash use was $283.6 million. Commercialization increased inventories by $40.2 million and receivables by $24.1 million; property and equipment purchases were $19.0 million. Revenue growth alone does not solve the financing problem. Autolus must improve margin and restrain expense while funding long-dated trials.
| Financial driver | Reported figure | Research interpretation |
|---|---|---|
| FY2025 total revenue | $75.4M | Commercial scale remained small relative to the operating cost base. |
| FY2025 operating loss | $270.5M | The organization was still structured for launch and multi-program development. |
| FY2025 net loss | $287.5M | Interest and revenue-interest liabilities added pressure below operating income. |
| Q1 2026 operating cash use | $65.3M | Cash burn improved from $75.6 million in Q1 2025 but remained high. |
| March 31, 2026 current ratio | 5.8x | Calculated from $368.8 million of current assets and $63.6 million of current liabilities; near-term liquidity was adequate. |
| April 2026 cost initiative | $15.0M annualized savings | Helpful but small relative to the FY2025 operating loss; execution and further leverage are necessary. |
Who owns Autolus stock, and why does it matter?
Each ADS represents one ordinary share with one vote, but ownership is concentrated. At March 1, 2026, 266.1 million shares were outstanding. BioNTech held 12.5%, MAK Capital 11.3%, Syncona 10.8%, BXLS V-Autobahn 8.9%, and directors and senior management 3.9%.
How do strategic shareholders affect governance?
BioNTech’s stake accompanied binder and technology rights, an obe-cel revenue interest and a conditional board-appointment right. Blackstone is both a shareholder and development-financing counterparty, while Syncona is a longstanding backer. Major holders may therefore receive revenue interests, milestones or governance rights in addition to share-price exposure.
| Holder / group | Stake at March 1, 2026 | Governance or economic relevance |
|---|---|---|
| BioNTech SE | 12.5% | Strategic collaborator, obe-cel revenue interest and conditional board-appointment rights. |
| MAK Capital Fund | 11.3% | Large specialist financial holder with material voting influence. |
| Syncona Portfolio | 10.8% | Longstanding life-sciences sponsor and major economic owner. |
| BXLS V-Autobahn | 8.9% | Blackstone-affiliated holder linked to development financing. |
| Directors and senior management | 3.9% | Provides equity alignment, although control remains dispersed among major outside holders. |
Christian Itin has led Autolus since 2016. The leadership page shows a management team spanning cell therapy, manufacturing, commercialization, finance and regulatory affairs. The board must balance launch execution, pipeline investment and access to capital.
What risks could weaken the Autolus outlook?
Autolus has one commercial product, one manufacturing network and a small initial market. Manufacturing deviation, slow adoption, reimbursement friction or safety concerns could affect enterprise value. AUCATZYL also carries boxed warnings for cytokine release syndrome, neurologic toxicities and secondary hematological malignancies.
Which risk is most visible in the financial statements?
Cash burn is the clearest near-term risk. Autolus ended Q1 2026 with $229.4 million of liquidity after using $65.3 million in operations. Cost reductions and revenue growth may help, but multi-year trials continue. A slower launch or clinical setback could accelerate the next financing, potentially under the influence of a concentrated investor base.
Why does Autolus matter for valuation?
A mature-company DCF is unsuitable because Autolus has negative cash flow and binary clinical outcomes. A useful model separates the adult ALL franchise from probability-adjusted pipeline programs. AUCATZYL depends on treated volume, net revenue, manufacturing success, cost per batch and revenue-sharing obligations. Pipeline value depends on clinical probability, launch timing, population, penetration and incremental manufacturing needs.
| Valuation driver | Current evidence | DCF implication |
|---|---|---|
| AUCATZYL revenue ramp | $26.2M in Q1 2026; $120M-$135M FY2026 guidance | Determines near-term scale and whether commercial infrastructure produces operating leverage. |
| Gross margin | 6.3% in Q1 2026 after negative FY2025 margin | Small changes materially affect cash burn because current revenue is concentrated in one product. |
| Operating expense | $61.2M combined R&D and SG&A in Q1 2026 | Defines the revenue level required before operating break-even. |
| Pipeline timing | MS and AUTO8 data in 2026; pediatric ALL in 2027; lupus nephritis in 2028 | Long-dated cash flows are highly sensitive to probability and discount rate. |
| Financing need | Runway expected into Q4 2027 | Potential future equity issuance changes per-share value even if enterprise value rises. |
| Revenue interests | Low-single-digit to potentially mid-single-digit BioNTech share plus other obligations | Model net cash retained by Autolus, not only gross product sales. |
Which KPIs should researchers monitor next?
What is the key takeaway from Autolus analysis?
Autolus is neither purely clinical-stage nor a mature commercial biopharma company. It has translated an academic CAR T design into an approved product, owned manufacturing and a broader platform. FY2025 established revenue; Q1 2026 established positive gross profit.
The tension is clear: adult ALL is narrow, losses remain large and Autolus must finance long studies while scaling patient-specific supply. AUCATZYL’s profile, Nucleus and specialist shareholders support the story; concentration, competition, reimbursement, clinical uncertainty and capital needs can weaken it.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.